The risk of cardiovascular disease in type 2 diabetes mellitus (SDT2) has been declining worldwide in recent decades. In April 2022, a study was published in the journal Diabetes, Obesity and Metabolism to assess the major risk factors for cardiovascular events in people with BPD over time from 2007 to 2020. Microangiopathic complications and administration of antidiabetic drugs at the same time.

The electronic health record (EHR) data of the Geisinger Health System (Geisinger), an integrated healthcare delivery system comprising> 100 patient facilities scattered throughout central and northeastern Pennsylvania (United States) were used for the study. A total of 95,461 patients with SDT2 who were followed for an average of 6.4 years were enrolled in the study. The primary endpoint of the study was an “ABCD” control markers that included: glycosylated hemoglobin HbA1c (<8%), blood pressure (systolic / diastolic blood pressure <140 / 90mmHg), cholesterol (Cholesterol) (non-HDL cholesterol <130mg / dL) and smoking (non-smoking). At the same time, the presence of microangiopathic complications and the commonly used categories of antidiabetic drugs were recorded.